Anbio Biotechnology (NNNN) Non-Current Assets (2023 - 2024)
Anbio Biotechnology (NNNN) posted quarterly Non-Current Assets of $387440.0 for Q4 2024, up 523.53% year-over-year from $62137.0 in Q1 2024, and up 523.53% quarter-over-quarter from $62137.0 in Q4 2023.
Anbio Biotechnology (NNNN) Non-Current Assets (2023 - 2024) Analysis & Trends
Anbio Biotechnology (NNNN) has reported Non-Current Assets for 2 consecutive years, with $387440.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Non-Current Assets rose 523.53% year-over-year to $387440.0; the TTM figure through Dec 2025 stood at $449577.0 (changed N/A YoY), while the FY2024 annual figure was $387440.0, up 523.53% from the prior year.
- Non-Current Assets advanced to $387440.0 in Q4 2024 per NNNN's latest filing, from $62137.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $387440.0 in Q4 2024 and bottomed at $62137.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.16 Bn | 128.94 Bn | 1.96 Bn | 11.33 Bn |
| 2 | Becton Dickinson | 52.48 Bn | 51.61 Bn | 2.32 Bn | 42.59 Bn |
| 3 | Alcon | 35.70 Bn | 34.34 Bn | 1.68 Bn | 24.47 Bn |
| 4 | Resmed | 33.66 Bn | 32.19 Bn | 861.22 Mn | 4.64 Bn |
| 5 | Medline | 29.16 Bn | 26.48 Bn | 2.22 Bn | 27.61 Bn |
| 6 | West Pharmaceutical Services | 25.04 Bn | 24.61 Bn | 329.20 Mn | 2.27 Bn |
| 7 | Solventum | 15.37 Bn | 14.96 Bn | 1.29 Bn | 10.50 Bn |
| 8 | Cooper Companies | 14.79 Bn | 14.65 Bn | 735.40 Mn | 10.18 Bn |
| 9 | Baxter International | 13.57 Bn | 11.42 Bn | 1.03 Bn | 12.80 Bn |
| 10 | Anbio Biotechnology | 294.35 Mn | 282.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 387,440.00 |
| Dec 31, 2023 | 62,137.00 |